SwePub
Sök i SwePub databas

  form:Ext_t

hints:Boolean_operators_t

Träfflista för sökning "AMNE:(SOCIAL SCIENCES Business and economics) ;srt2:(2010-2011);lar1:(liu);pers:(Dadfar Hossein)"

form:Search_simp_t: AMNE:(SOCIAL SCIENCES Business and economics) > (2010-2011) > swepub_uni:Liu_t > Dadfar Hossein

  • navigation:Result_t 1-6 navigation:of_t 6
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  • Dadfar, Hossein, et al. (creator_code:aut_t)
  • Board Effectiveness in Pharmaceutical Industry : The Case of TAPIC Pharmaceutical Group
  • 2011
  • record:In_t: Journal of Modern Accounting and Auditing. - : David Publication. - 1548-6583. ; 7:5, s. 463-473
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • This study suggests an emperically tested modelto fit the pharmaceutical industry and the context of LDCs, especially Iran. The paper stands upon a rich database consisting of Tamin Active Pharmaceutical Ingredients Investment Company (TAPIC) and its 11 subsidiary companies which are treated as 11 mini-cases. Data were collected by document analysis, questionnaire and interviews. The results suggest some improvements to the earlier models and show that the pattern of board effectiveness in Iranian pharmaceutical industry can be influenced by: (1) Internal factors including: (a) board members, the personality and background, (b) board composition, which is influenced by selection criteria, Tribalism, interpersonal relationship and belonging to the same ideological group, (c) board interactions, and (d) power distribution in the board, which is influenced by parenting power in holding companies. All internal factors are directly or indirectly affected by political issues as well as socio-cultural forces. (2) External factors including: (a) industrial complexity and the nature of industry, (b) industrial ethos, (c) legislation, and political forces, (d) economy, which the last two factors are influenced by international environment as well.
  •  
2.
  • Afazeli, Siamak, et al. (creator_code:aut_t)
  • Assessment of   Enterprise Quality and Export Performance: An Empirical Study on the Pharmaceutical Industry in IRAN
  • 2011
  • record:In_t: Proceedings QMOD Conference on Quality and Service Science 2011, 14th QMOD Conference 29st-31st August, 2011, San Sebastian, Spain: From LearnAbility & InnovaAbility to SustainAbility. - Pamplona, Spain : Servicios de Publicaciones Universidad de Navarra. ; , s. 55-73
  • swepub:Mat_conferencepaper_t (swepub:level_refereed_t)abstract
    • The main purpose of this study is to explore the relationship between export involvement and domestic market performance with focus on pharmaceutical firms. The study covers three research questions including: 1: How to assess the export involvement/performance of the Iranian pharmaceutical companies? 2: How to assess the performance of Iranian pharmaceutical companies in domestic market? 3: How to examine the relationship between export involvement/performance and domestic market performance? An intensive literature review and integration of relevant views and models helped us to build our own framework as a conceptual and analytical model. The model consists of EXPERF model, EFQM model, Export performance evaluation, domestic performance evaluation and the relationship between domestic performance and export performance. EFQM model and respective ILL indices was used for measuring domestic performance of the organizations on nine components of leadership, policy and strategy, people, partnership and resources, processes, people results, customer results, society results and key performance results. In order to achieve true representative of Iranian pharmaceutical companies K-mean clustering algorithm has been used to cluster Iranian pharmaceutical companies. EXPERF scale was used to measure export performance of the pharmaceutical companies in Iran on three aspects of financial export performance, strategic export performance and satisfaction with the export venture. Six clusters emerged after running the clustering algorithm in MATLAB software. This software enables us to put the similar companies together. Then centroids of the clusters were chosen to verify the relationship. Then relationship between export involvement (export performance) of pharmaceutical companies and their domestic performance was determined by use of Pearson coefficient. Pearson correlation = 0.708 and Sig= 0.026which is less than 0.0 5 then with 95% confidence we can claim that there is a significant relation between export performance of the Centroids and Domestic performance of the centroids of Iranian pharmaceutical companies and considering that the correlation coefficient value is positive, it means better export performance will result in better domestic performance. In other words Export performance of the companies has positive direct effect on domestic performance of Iranian pharmaceutical companies. Further studies can be done on clustering of Iranian pharmaceutical companies; effects of export involvement on individual components of EFQM based performance of firms and also verification of effect of export involvement and domestic performance in other business contexts.
  •  
3.
  • Dadfar, Hossein, et al. (creator_code:aut_t)
  • Organizational Innovation Capability, Product Platform Development and Performance: The  case of Iranian API companies, TAPIC subsidiaries
  • 2011
  • record:In_t: Proceedings QMOD Conference on Quality and Service Science 2011, 14th QMOD Conference 29st-31st August, 2011, San Sebastian, Spain. - Spain : Servicios de Publicaciones Universidad de Navarra. - 8480812117 ; , s. 481-503
  • swepub:Mat_conferencepaper_t (swepub:level_scientificother_t)abstract
    • This study attempts to explore (examine) the relationship between organizational innovation capability and product platform development as well as organizational performance in Active Pharmaceutical Ingredient (API) producer in Iran. Accordingly, a conceptual and analytical model for examining relationship of innovation capability of a firm with product platform development as well as performance  of API producers is developed which consisting of components:  strategy, processes, Linkage, organizational structure,  learning, product platform development and performance. The model is operationalized and tested in a group of Iranian API producers.The data were collected from eight subsidiaries companies of TAIC which are the largest conglomerate in production, provision and distribution of API in Iran. Our database consists of 168 questionnaires and companies, internal documents. Both quantitative and qualitative analyses were used as complementary to each other.1. The results show that most of Iranian API companies buy the required technology in order to establish a new product platform. This behavior was common among in both successful and unsuccessful firms. However, they were different in using the acquired technology for developing derivative products internally. The successful API producers (high performance) because of having better innovation capability are prone to use the opportunities to develop the new product derivatives, which can increase the sale and also the profit of company as well as its performance.2. There is a positive relationship between the organizational innovation capability and product platform development of the companies, and the firms which are better in innovation capability are prone to develop more products (derivatives) in the existing product platform when there is opportunity to develop new products and also there is a positive relationship between the performance of the companies and their innovation capabilities too, In which the firms which have the better innovation capabilities, have the better performance.3. Firms with good organizational innovation capability have a great possibility to develop their product platform as well as their organizational performance. Such firms had well communicated vision and mission, clear organizational purpose, long term commitment to the main projects, effective mechanisms to implement the innovation, systematic problem solving, proper organizational context, proper working structure, reward system, effective internal and external organizational systems, close relationship with customers, supplier and partners, commitment to training and development.
  •  
4.
  • Dadfar, Hossein, et al. (creator_code:aut_t)
  • Corporate Governance in Pharmaceutical Industry : The case of TAPIC Pharmaceutical Group
  • 2010
  • record:In_t: Proceedings of the 6th European Conference on Management Leadership and Governance. - Reading, UK : Academic Conferences Limited. ; , s. 83-93
  • swepub:Mat_conferencepaper_t (swepub:level_scientificother_t)abstract
    • Pharmaceutical industry plays a strategic role in economy of Iran. Corporate governance, in pharmaceutical companies as the very core of an organization, and the driving force of corporate leadership, plays a significant role in business success and overall productivity of the firms. As yet, the characteristics, factors causing success and failure of core governance in Iranian pharmaceutical industry have remained unsearched. Furthermore, the applicability of western theories and models to the traditional societies such as Iran are largely unknown. This study is an attempt to explore the pattern of corporate governance and firm performance in Iranian pharmaceutical industry and suggests an alternative good governance model suitable to apply to less developed countries (LDC) pharmaceutical industry, with emphasis on Iranian context.
  •  
5.
  • Dadfar, Hossein, et al. (creator_code:aut_t)
  • Evaluating Export Readiness : A Framework for Analysis
  • 2011
  • record:In_t: Conference Proceedings of the LCBR European Marketing Conference 2011. - Frankfurt : The Lupcon Center for Business Research.
  • swepub:Mat_conferencepaper_t (swepub:level_scientificother_t)abstract
    • This study attempts to: 1) build a comprehensive framework for assessment of export readiness of developing countries’ firms, and 2) evaluate export readiness of Iranian firms. The study database consists of 12 cases (companies) and 21 experts’ views who suggested “good export practices”. Our data includes: in-depth interviews, self-administered questionnaire and documents analysis. Both quantitative and quantitative analyses are used. By gap analysis of current and desired/accepted situation, the degrees of readiness are explored. The study is resulted in a framework, which is developed upon integration of the earlier literature and models, empirically tested and verified covers evaluation of: corporate Profile, export Awareness, export Readiness, and export Operation (PARO model).
  •  
6.
  • Peyrovan, Sanaz, et al. (creator_code:aut_t)
  • Structuring the pharmaceutical parent company organization : A value-based approach, The Case of TPICO
  • 2010
  • record:In_t: IASK International Conference Global Management. - : International Association for the Scientific Knowledge. - 9789898295019 ; , s. 471-476
  • swepub:Mat_conferencepaper_t (swepub:level_scientificother_t)abstract
    • Today’s, the parent company has the great role in managing and monitoring subsidiaries and companies and promoting their industrial activities. But, the main problem for pharmaceutical parent companies is the lack of clarity and confusion of   responsibilities between units .The successful parenting needs to create the element of 'fit' between the ways parent operates – parent characteristics – and   its business characteristics. However, the main parent characteristic is parent structure and restructuring is the main challenge in changing and unstable pharmaceutical market. In fact, the parent strategy should determine how value can be added to every organizational structure and parent structure should be proportionate to its dominant value creation strategy. The value drivers are very different in pharmaceutical industry regarding fast changing technology. The aim of this study is to explore an appropriate value-creating structure for the largest pharmaceutical parent company in Iran, TPICO. This study concentrates the sources of value in this special domain and restructuring the parent company by considering the dominant value-creating strategy and pharmaceutical value drivers.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-6 navigation:of_t 6

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t